Supportive Care in Cancer · Nov 21, 2026
Multimodal lifestyle strategies for ADT-induced osteosarcopenia and metabolic dysfunction in prostate cancer
By Ambrosio F, Persia M, Bellieni A et al.
Background Androgen deprivation therapy (ADT) is associated with significant changes in body composition, promoting bone and muscle loss and increasing the risk of osteosarcopenia. This condition predisposes patients to adverse events such as falls, fractures, loss of functional autonomy, and increased cardiovascular risk, with possible repercussions on oncological outcomes and, in general, on patients’ quality of life. Objectives This narrative review explores the available evidence on the role of exercise, nutrition, and the use of drug therapies in the prevention and management of ADT-induced osteosarcopenia, identifying the future perspectives in the integrated management of patients with prostate cancer undergoing hormone treatment. Methods This review explores studies published over the last 15 years and aims to select scientific contributions concerning the effects of physical exercise, nutrition, or combined interventions on musculoskeletal health in subjects undergoing androgen deprivation therapy. Results Resistance training represents a promising non-pharmacological approach for the management of ADT-induced musculoskeletal alterations. Such programs have demonstrated efficacy in preserving lean body mass, potentially mitigating bone loss, and improving physical performance. While antiresorptive agents remain the primary intervention for bone preservation, lifestyle measures constitute an essential component of a multimodal approach to the care of patients undergoing ADT. Conclusions Preventing ADT-induced osteosarcopenia is a critical challenge for the quality of life of men with prostate cancer. Current research and clinical care trends are moving toward flexible, integrated models that include exercise and nutrition in standard, patient-centered cancer care pathways. The early integration of these interventions into clinical pathways represents a concrete prospect for improving overall outcomes in patients with prostate cancer. Long-term randomized studies with functional and molecular endpoints are desirable to validate and personalize preventive strategies.